PMID: 8100643Jan 1, 1993

Tardive dyskinesia

Schizophrenia Bulletin
D V Jeste, M P Caligiuri

Abstract

Neuroleptic-induced tardive dyskinesia (TD) continues to be a serious problem in the psychopharmacology of schizophrenia. The overall mean prevalence of TD among chronically neuroleptic-treated patients is approximately 24 percent. The annual incidence in younger adults is 4 to 5 percent. Aging is a major risk factor for TD. Our ongoing prospective study suggests that the annual incidence in patients over age 45 is over 30 percent. Other likely risk factors include female gender, mood disorders, "organic" brain dysfunction or damage, diabetes mellitus, and early extrapyramidal side effects. Metoclopramide, a D2-receptor blocker commonly used in non-psychiatric medical patients, can also produce persistent TD. TD can best be assessed for research purposes by a combination of subjective and objective methods. In recent years, several instrumental procedures have been developed to objectively quantify various abnormal movements. The advantages and limitations of the traditional rating scales and the newer instrumental approaches are discussed. The course of TD is variable but often not progressive. The early theory that striatal dopamine receptor supersensitivity causes TD has now given way to the hypothesis of multiple neurotrans...Continue Reading

Citations

Apr 24, 2007·Neurotoxicity Research·Richard M KostrzewaRyszard Brus
Oct 7, 2006·Journal of Neural Transmission·T Archer, R J Beninger
Nov 1, 1994·Biological Psychiatry·D D SewellD V Jeste
Dec 29, 1995·European Journal of Pharmacology·L Antkiewicz-MichalukJ Vetulani
Jul 31, 1996·Psychiatry Research·T L PattersonD V Jeste
Oct 1, 1995·Progress in Neuro-psychopharmacology & Biological Psychiatry·Y OhnoM Nakamura
Mar 1, 1995·Journal of Clinical Forensic Medicine·P F BuckleyG Gardner
Oct 20, 1998·Biological Psychiatry·D A WirshingS R Marder
Jun 22, 1999·Biological Psychiatry·G BartzokisJ Mintz
Mar 23, 2002·European Journal of Pharmacology·Alessandro SerrettiEnrico Smeraldi
Oct 30, 1998·Journal of Psychiatric Research·D V JesteM P Caligiuri
Jan 13, 1999·Pediatric Clinics of North America·R L FindlingJ L Blumer
Jul 23, 2003·Pharmacology, Biochemistry, and Behavior·Donard S Dwyer, Dallas Donohoe
Dec 1, 1996·Social Science & Medicine·D DingelstadN Vakas
Sep 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Siu-Kau LeungTony Leung
Jul 10, 2002·Research in Developmental Disabilities·Johnny L MatsonC Scott Eckholdt
Aug 24, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·E M Haberfellner
Apr 25, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Hasan HerkenHaluk A Savaş
Jan 27, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J Fritze, I Spreda
Feb 7, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M KaneN R Schooler
Mar 30, 2011·Telemedicine Journal and E-health : the Official Journal of the American Telemedicine Association·Vijay AmarendranCalvert Warren
Oct 6, 2000·Clinical Neuropharmacology·Chanoch MiodownikM Kotler
Nov 1, 1995·Journal of the American Academy of Child and Adolescent Psychiatry·D F ConnorK R Ozbayrak
Nov 9, 2002·American Journal of Therapeutics·Prakash S MasandBradford Frank
Jun 13, 2003·The Neurologist·Hubert H Fernandez, Joseph H Friedman
Aug 2, 2008·Clinical Neuropharmacology·Chanoch MiodownikVladimir Lerner
Oct 9, 2007·Current Opinion in Psychiatry·Jessica Broadway, Jacobo Mintzer
Mar 2, 2005·Journal of Clinical Psychopharmacology·Mario Rodrigues Louzã, Debora Pastore Bassitt
Jun 7, 1994·The Journal of Pharmacy Technology : JPT : Official Publication of the Association of Pharmacy Technicians·J P LacroP L Gilbert
Apr 30, 2002·British Journal of Nursing : BJN·Jean Taylor
Sep 20, 1997·Acta Psychiatrica Scandinavica·L A LabbateM A Oleshansky
Sep 8, 1998·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·S A McDermidE D'Alessandro
May 20, 1999·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·M MagulacD V Jeste
Jan 27, 2006·The Cochrane Database of Systematic Reviews·Karla Soares-Weiser, John Rathbone
Jul 2, 2005·Journal of Psychiatric Practice·J C ChouM Serper
Feb 7, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Jan 18, 2018·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserHanna Bergman
Mar 13, 2018·Current Opinion in Psychiatry·Clement C ZaiJames L Kennedy
Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo
Apr 1, 1996·The Journal of Nervous and Mental Disease·L A McAdamsD V Jeste
May 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·P Wright, M Taylor
Sep 20, 1997·Acta Psychiatrica Scandinavica·J van OsR Murray
Jun 12, 1999·Journal of the American Geriatrics Society·D V JesteM P Caligiuri
Jul 2, 2011·Journal of Clinical Psychopharmacology·Sofia N ChatziioannouLefteris Lykouras
Nov 11, 2011·The Cochrane Database of Systematic Reviews·Adib EssaliClive E Adams
Apr 25, 2007·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Vita DolzanKatja Breskvar
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserJohn McGrath
Aug 25, 2015·Therapeutic Advances in Psychopharmacology·Annica BergendalKarin Sparring Björkstén
Jul 30, 2016·Pharmacogenomics·Rachel K LanningDaniel J Müller
Aug 16, 2017·Health Technology Assessment : HTA·Hanna BergmanClive E Adams
Sep 8, 2017·CNS Spectrums·Martin StrassnigPhilip D Harvey
Oct 5, 2018·Frontiers in Pharmacology·Clement C ZaiJames L Kennedy
May 1, 1999·Acta Psychiatrica Scandinavica·J van OsS G Thompson
Mar 5, 1999·Journal of Psychopharmacology·R Tranter, D Healy
Feb 18, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·D S HarrisV I Reus
Mar 11, 2004·Acta Psychiatrica Scandinavica·S SilvestriP Seeman
Oct 26, 2018·Neurochemical Research·Toyanji Joseph PunchaichiraB K Thelma
Mar 27, 2018·The Cochrane Database of Systematic Reviews·Adib EssaliClive E Adams
Feb 9, 2021·Frontiers in Neuroscience·Frank S MennitiChristopher J Schmidt

Related Concepts

Dyskinesia, Medication-Induced
Schizophrenia
Antipsychotic Effect

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here